Skip to main content
Premium Trial:

Request an Annual Quote

Foundation, Ariad Partner on Genomic Profiles of Lung Cancer Patients

NEW YORK (GenomeWeb News) – Foundation Medicine and Ariad Pharmaceuticals today announced a deal aimed at the genomic profiling of patients enrolled in clinical trials for Ariad's investigational dual-inhibitor of ALK and EGFR for non-small cell lung cancer and other cancers.

The firms will collaborate on the generation of genomic profile information for patients enrolled in Ariad's ongoing Phase 1/2 trial for its drug AP26113, and data will be matched with clinical observations to better understand the activity and selectivity of the drug, Foundation and Ariad said.

Financial and other terms of the deal were not disclosed.

"This study is an example of how cancer complexity often defies single-marker analysis in drug development," Foundation President and CEO Michael Pellini said in a statement. "We expect that our comprehensive genomic profile will help to identify the optimal patient population for AP26113 and may potentially enable an expedited development timeline."

On Monday the Cambridge, Mass.-based firm announced a deal with AstraZeneca to identify genomic mutations in cancer-related tumor genes.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.